CG
TGTX icon

Cutler Group’s TG Therapeutics TGTX Stock Holding History

Cutler Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$16K Hold
3,000
– – 0.01% 1097
2023
Q4 		$2K Buy
+3,000
New +$34.9K ﹤0.01% 3195
2023
Q1 		– Sell
-32,200
Closed -$27K – 4707
2022
Q4 		$27K Buy
+32,200
New +$234K ﹤0.01% 2009
2022
Q2 		– Sell
-29,000
Closed -$15K – 5671
2022
Q1 		$15K Buy
29,000
+9,800
+51% +$113K ﹤0.01% 3300
2021
Q4 		$36K Sell
19,200
-9,400
-33% -$244K ﹤0.01% 2657
2021
Q3 		$151K Buy
28,600
+25,000
+694% +$773K 0.01% 1585
2021
Q2 		$18K Buy
3,600
+2,600
+260% +$102K ﹤0.01% 3407
2021
Q1 		$20K Sell
1,000
-1,900
-66% -$91.3K ﹤0.01% 3226
2020
Q4 		$39K Buy
2,900
+500
+21% +$16.9K ﹤0.01% 2189
2020
Q3 		$13K Buy
2,400
+1,400
+140% +$32.2K ﹤0.01% 2799
2020
Q2 		$4K Buy
+1,000
New +$16.1K ﹤0.01% 3505
2020
Q1 		– Sell
-5,000
Closed -$9K – 4651
2019
Q4 		$9K Hold
5,000
– – ﹤0.01% 2711
2019
Q3 		$1K Hold
5,000
– – ﹤0.01% 3831
2019
Q2 		$8K Hold
5,000
– – ﹤0.01% 2845
2019
Q1 		$10K Sell
5,000
-3,400
-40% -$18.4K ﹤0.01% 2507
2018
Q4 		$4K Buy
+8,400
New +$41.7K ﹤0.01% 3072
2018
Q3 		– Sell
-11,500
Closed -$5K – 4690
2018
Q2 		$5K Buy
11,500
+500
+5% +$6.88K ﹤0.01% 3140
2018
Q1 		$14K Sell
11,000
-5,700
-34% -$72.8K ﹤0.01% 2549
2017
Q4 		$5K Sell
16,700
-26,500
-61% -$232K ﹤0.01% 3670
2017
Q3 		$83K Sell
43,200
-2,500
-5% -$28.5K ﹤0.01% 1819
2017
Q2 		$68K Buy
45,700
+26,700
+141% +$299K ﹤0.01% 2185
2017
Q1 		$21K Buy
+19,000
New +$136K ﹤0.01% 3286
2016
Q1 		– Sell
-6,100
Closed -$2K – 7193
2015
Q4 		$2K Buy
+6,100
New +$77K ﹤0.01% 5655

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cutler Group's TGTX Position: Q1 2024 in Review

Cutler Group sold out of TG Therapeutics (TGTX) in Q1 2024, closing a stake of 2,080 shares — an estimated $33.1K sold.

Cutler Group first reported a position in TGTX in Q4 2015 and held it in 26 quarters. The position peaked at $141K in Q3 2021. 243 funds tracked by Wall St. Rank hold TGTX as of Q1 2024.

  • Cutler Group reported no remaining TG Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Cutler Group sold 2,080 TG Therapeutics shares in Q1 2024, an estimated $33.1K.
  • Cutler Group first reported a position in TG Therapeutics in Q4 2015 and held it in 26 quarters.
  • Cutler Group's TG Therapeutics position peaked at $141K in Q3 2021.
  • 243 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.